tiprankstipranks
Sanofi SA (SNY)
NASDAQ:SNY
US Market
SNY
Sanofi
RESEARCH TOOLSreports

Sanofi (SNY) Stock News & Sentiment

2,213 Followers
Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
Premium
Ratings
Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
4d ago
SNY
Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
Premium
Market News
Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
9d ago
NVO
SNY
Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data
Premium
Company Announcements
Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data
11d ago
6K
SNY
HLTH, ESIH, HLT: Look to Europe for Healthcare ETFs
Premium
Market News
HLTH, ESIH, HLT: Look to Europe for Healthcare ETFs
16d ago
AZN
HLT
Sanofi Wins FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease
Premium
Company Announcements
Sanofi Wins FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease
19d ago
6K
SNY
Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update
Premium
Company Announcements
Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update
23d ago
SNY
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease
Premium
Company Announcements
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease
27d ago
SNY
REGN
More SNY News >

SNY News on the Web

Sanofi becomes market authorization holder for Nuvaxovid in Canada
TipRanks News
Neutral
Dianthus initiated with an Outperform at Wolfe Research
TipRanks News
Neutral
Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
TipRanks News
Neutral
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Zacks
Neutral
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
Zacks
Neutral
Sanofi's Lunsekimig Shows Promise In Respiratory Diseases
rttnews
Bullish
Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies
rttnews
Bullish
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Zacks
Neutral

News Score - Last 7 Days

Positive
SNY
Sector Average
Media Buzz
This Week9 articles
Weekly Average11.5 articles
News Sentiment
This Week99%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SNY’s Media Buzz Sentiment?
9 articles about SNY were published this week. In an average week, 11.5 articles are published.
    What is SNY’s weekly average amount of articles?
    In an average week, 11.5 articles about SNY are published.
      What is SNY’s News Sentiment?
      99% of articles about SNY were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week